Purpose: The purpose of this article is to examine visual acuity (VA) outcomes and treatment patterns in neovascular age-related macular degeneration (nAMD) eyes switching between ranibizumab and aflibercept in routine clinical practice. Methods: Electronic medical records were used to identify nAMD eyes receiving ranibizumab or aflibercept with 12 months’ follow-up since switching antivascular endothelial growth… Read More »
Pravin U. Dugel, Adrian Koh, Yuichiro Ogura, Glenn Jaffe, Ursula Schmidt-Erfurth, David Brown, Andre V. Gomes, James Warburton, Andreas Weichselberger, Frank G. Holz Abstract ObjectiveTwo similarly designed, phase 3 trials (HAWK and HARRIER) compared brolucizumab, a single-chain antibody fragment that inhibits vascular endothelial growth factor-A, with aflibercept to treat neovascular age-related macular degeneration (AMD). DesignDouble-masked, multicenter, active-controlled, randomized trials. Patients(N = 1817) with untreated,… Read More »
Pravin Dugel, MD, R. Ross Lakhanpal, MD Channels: Retina | Posted 4/5/2019 Pravin Dugel, MD, joins Ross Lakhanpal, MD, to define, discuss, and forecast the future of informatics in retina. In Dr. Dugel’s view, the informatics platforms used in other fields could translate to retina and, when they arrive, will change the preparation and… Read More »
RWC Unplugged offers participants a unique opportunity to learn, share and discuss controversial topics in retina with a large group of industry experts and clinical leaders. With no scripts or industry commercials, this event evokes deep discussions moderated by KOLs, who encourage attendees to challenge their perspectives in lively, no-holds-barred discussions, with live polling on… Read More »
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to provide an update on progress with the ongoing Phase I/II clinical trial of its hRPC cell therapy candidate in the blindness-causing disease, retinitis pigmentosa (RP). The Company is pleased to report that all three of the first… Read More »
ROCKVILLE, Md., Feb. 14, 2019 /PRNewswire/ — REGENXBIO Inc. (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, will host an analyst and investor event focused on its ophthalmology program, including its lead product candidate RGX-314, on Thursday, February 21,… Read More »
Derek Kunimoto, MD, JD; Masahito Ohji, MD; Raj K. Maturi, MD; Tetsuju Sekiryu, MD; Ying Wang, MD, PhD; Grace Pan, MS; Xiao-Yan Li, MD; Susan Schneider, MD; for the BAMBOO and CYPRESS Study Groups BACKGROUND AND OBJECTIVE: To evaluate comparability of abicipar pegol (abicipar) effects in patients with treatment-naïve neovascular age-related macular degeneration (nAMD) in… Read More »
PHOENIX (Feb. 11, 2019)– Retinal Consultants of Arizona & the Retinal Research Institute – one of the nation’s leading retina & vitreous clinical research and patient treatment facilities – is proud to announce that Dr. Pravin U. Dugel has conducted the first stem cell therapy treatment for patients with retinitis pigmentosa (RP) in Arizona. The… Read More »
Graybug Vision Presents Top Line Results of Phase 1/2a ADAGIO Study at Hawaiian Eye & Retina 2019 ADAGIO Study Provides Evidence that GB-102 Can Achieve Sustained-Drug Delivery in the Treatment of Wet Age-Related Macular Degeneration (AMD) Graybug Vision’s novel investigational depot approach is designed to continuously inhibit activity of all VEGF receptors for the treatment… Read More »
An Independent Analysis of Protocol i Study Data Dugel, Pravin U., MD*,†; Campbell, Joanna H., PhD‡; Kiss, Szilárd, MD§; Loewenstein, Anat, MD¶; Shih, Vanessa, PharmD‡; Xu, Xiaoshu, MS‡; Holekamp, Nancy M., MD**; Augustin, Albert J., MD, PhD††; Ho, Allen C., MD‡‡; Gonzalez, Victor H., MD§§; Whitcup, Scott M., MD¶¶ RETINA: January 2019 – Volume 39… Read More »
